Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409880 | 1.00 | GAA (0.43) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL8813314 | 0.83 | MEN1 (0.44) | GAASCN5ASCN9AALDH1A1 | |
| SCHEMBL10869954 | 0.81 | ALDH1A1 (0.49) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL11305185 | 0.81 | ALDH1A1 (0.49) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL5385328 | 0.81 | ALDH1A1 (0.49) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL28570454 | 0.81 | ALDH1A1 (0.49) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL355604 | 0.81 | ALDH1A1 (0.49) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL11288238 | 0.79 | GAA (0.45) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL10357746 | 0.79 | SCN5A (0.55) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL11291699 | 0.79 | GAA (0.45) | GAASCN5ASCN9ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097388-A1 | SYSTEMS AND METHODS FOR MONITORING FATTY ACID METABOLISM | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2024097388-A1 | SYSTEMS AND METHODS FOR MONITORING FATTY ACID METABOLISM | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230251278-A1 | ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT | RIKEN (JP) | 2023-08-10 | — | — | US | disclosed |
| US-7402405-B2 | Methods and kits for diagnosing a pancreatic-based fat malabsorption disorder | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1404861-A4 | METHODS AND KITS FOR DIAGNOSING A PANCREATIC-BASED FAT MALABSORPTION DISORDER | PHILADELPHIA CHILDREN HOSPITAL (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1404861-A1 | METHODS AND KITS FOR DIAGNOSING A PANCREATIC-BASED FAT MALABSORPTION DISORDER | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030086869-A1 | Methods and kits for diagnosing a pancreatic-based fat malabsorption disorder | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2003-05-08 | — | — | US | disclosed |
| WO-2002099123-A1 | METHODS AND KITS FOR DIAGNOSING A PANCREATIC-BASED FAT MALABSORPTION DISORDER | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230251278-A1 | ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT | LIPC, MTTP, CETP | GAA 526/4885SCN5A 3535/4885SCN9A 2624/4885 |
| US-20030086869-A1 | Methods and kits for diagnosing a pancreatic-based fat malabsorption disorder | PNLIP, FABP2, FABP6 | GAA 38/4885SCN5A 2276/4885SCN9A 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.